Side-by-side comparison of AI visibility scores, market position, and capabilities
NYC YC W20 MSK Cancer Center spinout with FDA Breakthrough Device for whole-genome/transcriptome tumor profiling;
Isabl is a New York-based whole-genome and transcriptome cancer diagnostics company — backed by Y Combinator (W20) with $5 million in total funding including $3 million from Two Sigma Ventures, BoxOne Ventures, Bossa Invest, and Jude Gomilla, plus a $2 million SBIR grant from the National Cancer Institute (NCI) — commercializing the Isabl GxT (Genome x Transcriptome) diagnostic platform that received FDA Breakthrough Device Designation for comprehensive tumor profiling that analyzes entire tumor genomes and transcriptomes simultaneously to identify cancer-associated mutations, fusion genes, and expression patterns that guide treatment selection. Founded in 2020 after incubating at Memorial Sloan Kettering Cancer Center (MSKCC) from 2015-2019, Isabl's genomic testing platform is specifically advancing through March 2025 NCI funding for pediatric and rare solid cancers where comprehensive genomic profiling can identify targeted therapy opportunities that standard panel tests miss.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.